ScreenerHero

YARW Yarrow Bioscience, Inc.

NAS · US · Healthcare · Biotechnology · yarrowbioscience.com
18.77USD+0.24%Mkt Cap: 174.69M $P/E: —

Yarrow Bioscience, Inc. operates as a clinical-stage biotechnology company that engages in developing transformative therapies for autoimmune thyroid diseases. The company's candidate, YB-101, is a humanized monoclonal a…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap174.69M USD
Enterprise Value138.26M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-283.98M USD
Revenue/Share—
Last Price18.77 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees7
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-11.35
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B-0.72
EPS (TTM)—
EPS (Forward)-1.65
52W Range
15.8010% of range46.95
52W High46.95 USD
52W Low15.80 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE—
ROA—
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF560.00K USD
CapEx (TTM)—
FCF Margin—
FCF Yield—
Net Debt-18.67M USD
Net Debt/EBITDA—
Balance Sheet
Debt/Equity—
Current Ratio1.40
Quick Ratio1.40
Book Value/Sh-26.06 USD
Cash/Share6.13 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div DateJul 24, 2026
Pay DateJul 23, 2026
Splits
Last Split1:50
Split DateJul 27, 2026
Analyst Consensus
Rating—
Target (Mean)57.00 USD
Upside (mean)+203.6%
Target Range56.00 USD – 58.00 USD
56.00+203.6% to mean58.00
# Analysts2
Ownership
Shares Out.9.30M
Float1.75M
Insiders2.02%
Institutions27.62%
Short Interest
Short Ratio1.1d
Short % Out.1.36%
Shares Short126.53K
Short (prev mo.)19.43K
Technical
SMA 5032.59 (-42.4%)
SMA 20031.63 (-40.6%)
Beta2.08
S&P 52W Chg16.45%
Avg Vol (30d)129.33K
Avg Vol (10d)138.32K
Technical Indicators
RSI (14)26.7
MACD-3.7061
MACD Signal-3.2072
MACD Hist.-0.4990
BB Upper32.44 USD
BB Middle25.38 USD
BB Lower18.33 USD
BB Width55.58%
ATR (14)2.753 USD
Vol Ratio (20d)0.85x